DEVEXPERTS
Devexperts, a software provider for the financial industry, launched DXtrade, a new SaaS (Software-as-a-Service) trading platform for the retail FX and CFD industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005154/en/
DXtrade is an off the shelf trading solution for CFD brokers with robust risk management and back office applications. Its flexibility in settings allows brokers to achieve their ideal setup in both their trading platform front ends and brokerage operations.
DXtrade has been designed as a trading platform that allows brokers to differentiate themselves from the wider market as all layouts and setups of the platform are determined by the broker. This high degree of automation and customisation also extends to the back-end configurations where brokers can set up limits, rebates, margins, spreads, and client execution on instruments, group or individual client levels. This allows brokers to create custom offerings for multiple client segments worldwide.
DXtrade also offers several proprietary trading tools designed to enhance the user experience and improve both client acquisition and retention. These built-in tools encompass custom trading journals, dashboards, modern navigation, and more, on a highly intuitive mobile and web UIs.
Conor O’Driscoll , VP of OTC Platform commented: “At Devexperts we have been experts in building custom trading solutions for top brokerage firms for over 18 years and DXtrade is the culmination of such efforts, allowing us to offer our technology to the wider CFD market. CFD brokers are currently experiencing a significant rise in the amount of customers and volumes traded on their platforms. As a result, we know how important it is for brokers to differentiate in a highly congested market and we firmly believe that DXtrade is the innovative solution necessary for brokers to take their offering to the next level.”
The platform is fully maintained and hosted by Devexperts. To request the demo of DXtrade visit https://dx.trade/
About Devexperts
Devexperts specializes in the development of software solutions for the Capital Markets industry. Their clients are brokerage houses, exchanges and wealth management firms. Devexperts are the developers of the thinkorswim platform and numerous recognized and reliable applications, with millions of people across the global financial sector trading daily using their technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA appoints CEO of newly established AI Company NTT DATA AIVista, Inc.9.12.2025 14:00:00 CET | Press release
Dr. Bratin Saha joins NTT DATA AIVista, Inc., bringing extensive experience in AI, infrastructure, platforms and solutions NTT DATA AIVista, Inc. established in Silicon Valley to help NTT operating companies accelerate the launch and scaling of AI native businesses NTT DATA, a global leader in AI, digital business and technology services, today announced the appointment of Dr. Bratin Saha as CEO of the newly established AI Company, NTT DATA AIVista, Inc., effective Dec 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209189202/en/ Dr. Bratin Saha, newly appointed CEO of NTT DATA AIVista, Inc. Saha brings deep expertise in AI, infrastructure, platforms and solutions; scaling new businesses and significant ecosystem relationships. Prior to joining NTT DATA, he held executive positions at NVIDIA, Amazon Web Services (AWS) and most recently DigitalOcean. At NVIDIA, Saha served as Vice President of Software Infrastructu
Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 20269.12.2025 14:00:00 CET | Press release
Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1x1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Francisco from January 12 to 15, 2026. Aqemia will be represented by Maximilien Levesque, CEO and co-founder, Emmanuelle Martiano, COO and co-founder, and Théa Vu-Bignand, VP Finance. Powered by QEMI, its proprietary physics-based generative AI engine for therapeutic molecule invention, Aqemia designs novel drug candidates in a repeatable, efficient, and scalable way. The company focuses on advancing its internal preclinical pipeline while establishing partnerships that validate its platform and scientific differentiation, with the ambition to accelerate the delivery of new therapies in areas of high unmet medical need. About Aqemia Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI
Avia Expands to Europe with New German Subsidiary9.12.2025 14:00:00 CET | Press release
AviaGames, a leading global mobile skill-based gaming platform, today announced the establishment of a new subsidiary in Germany. Games industry veteran Michelle Zou has been appointed to head the new entity, overseeing market expansion and investment initiatives across Europe. This move marks a significant milestone in AviaGames’ global growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209920028/en/ Games industry veteran Michelle Zou has been appointed to head the AviaGames German subsidiary, overseeing market expansion and investment initiatives across Europe. AviaGames has rapidly emerged as one of the most prominent interactive entertainment companies worldwide, with a global user base of tens of millions of players across North America, and Europe, spanning North America and beyond. The company is especially recognized for its popularity among female players and for delivering high-quality, skill-based
ExaGrid Wins 3 New Industry Awards at the MSP Channel Awards9.12.2025 14:00:00 CET | Press release
Awards highlight ExaGrid’s achievements in the MSP sector ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the company was honored with three awards during the 1st annual MSP Channel Awards ceremony, held in London on December 3, 2025, including: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209577454/en/ Photo courtesy of MSP Channel Awards. Backup & DR Innovation of the Year Storage Hardware Innovation of the Year Storage Vendor of the Year Many Managed Service Providers (MSPs) use ExaGrid Tiered Backup Storage to offer their customers Backup as a Service (BaaS), Disaster Recovery as a Service (DRaaS), and IT Data Center Outsourcing. In 2025, ExaGrid released new features that help MSPs track their customers’ d
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 13:00:00 CET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom